.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Accenture
Fuji
Citi
QuintilesIMS
Federal Trade Commission
Express Scripts
Moodys
Cerilliant
Julphar

Generated: December 16, 2017

DrugPatentWatch Database Preview

Bristol Myers Company Profile

« Back to Dashboard

What is the competitive landscape for BRISTOL MYERS, and when can generic versions of BRISTOL MYERS drugs launch?

BRISTOL MYERS has eighty-three approved drugs.

There are eighteen US patents protecting BRISTOL MYERS drugs and there have been three Paragraph IV challenges on BRISTOL MYERS drugs in the past three years.

There are four hundred and fifty-seven patent family members on BRISTOL MYERS drugs in fifty-eight countries and one hundred and seventy-three supplementary protection certificates in fifteen countries.

Summary for Bristol Myers

International Patents:457
US Patents:18
Tradenames:71
Ingredients:61
NDAs:83
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers SquibbMONOPRIL-HCTfosinopril sodium; hydrochlorothiazideTABLET;ORAL020286-001Nov 30, 1994DISCNYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbVESPRINtriflupromazine hydrochlorideTABLET;ORAL011123-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbGLUCOPHAGE XRmetformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL021202-001Oct 13, 2000AB1RXYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbSPRYCELdasatinibTABLET;ORAL021986-004May 30, 2008ABRXYesYes► Subscribe► SubscribeYY► Subscribe
Bristol Myers SquibbCOUMADINwarfarin sodiumTABLET;ORAL009218-016Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
Bristol MyersQUESTRAN LIGHTcholestyraminePOWDER;ORAL019669-003Dec 5, 1988DISCNYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbTUBOCURARINE CHLORIDEtubocurarine chlorideINJECTABLE;INJECTION005657-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol MyersNUPRINibuprofenTABLET;ORAL072035-001Feb 16, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol MyersQUESTRAN LIGHTcholestyraminePOWDER;ORAL019669-001Dec 5, 1988DISCNYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbSPRYCELdasatinibTABLET;ORAL021986-005Oct 28, 2010RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bristol Myers

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers SquibbSUSTIVAefavirenzCAPSULE;ORAL020972-001Sep 17, 1998► Subscribe► Subscribe
Bristol Myers SquibbHYDREAhydroxyureaCAPSULE;ORAL016295-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Bristol Myers SquibbMONOPRIL-HCTfosinopril sodium; hydrochlorothiazideTABLET;ORAL020286-002Nov 30, 1994► Subscribe► Subscribe
Bristol Myers SquibbZERITstavudineCAPSULE;ORAL020412-004Jun 24, 1994► Subscribe► Subscribe
Bristol Myers SquibbVIDEXdidanosineFOR SOLUTION;ORAL020155-006Oct 9, 1991► Subscribe► Subscribe
Bristol Myers SquibbMONOPRILfosinopril sodiumTABLET;ORAL019915-004Mar 28, 1995► Subscribe► Subscribe
Bristol Myers SquibbVIDEX ECdidanosineCAPSULE, DELAYED REL PELLETS;ORAL021183-004Oct 31, 2000► Subscribe► Subscribe
Bristol Myers SquibbVIDEXdidanosineTABLET, CHEWABLE;ORAL020154-003Oct 9, 1991► Subscribe► Subscribe
Bristol Myers SquibbBUSPARbuspirone hydrochlorideTABLET;ORAL018731-004Apr 22, 1996► Subscribe► Subscribe
Bristol Myers SquibbVIDEXdidanosineTABLET, CHEWABLE;ORAL020154-005Oct 9, 1991► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BRISTOL MYERS drugs

Drugname Dosage Strength Tradename Submissiondate
apixabanTablets2.5 mg and 5 mgELIQUIS12/28/2016
efavirenzCapsules50 mg, 100 mg and 200 mgSUSTIVA11/3/2016
naloxone hydrochlorideNasal Spray4 mg/sprayNARCAN7/15/2016
dasatinibTablets80 mg and 140 mgSPRYCEL6/17/2011
dasatinibTablets80 mg and 140 mgSPRYCEL6/16/2011
dasatinibTablets20 mg, 50 mg, 70 mg and 100 mgSPRYCEL6/28/2010
entecavirTablets0.5 mg and 1 mgBARACLUDE6/14/2010
atazanavir sulfateCapsules100 mg and 150 mgREYATAZ3/19/2010
atazanavir sulfateCapsules200 mgREYATAZ2/16/2010
atazanavir sulfateCapsules300 mgREYATAZ7/20/2009
efavirenzTablets600 mgSUSTIVA4/9/2009
pravastatin sodiumTablets30 mgPRAVACHOL6/1/2005
didanosineDelayed-release Capsules200 mg, 250 mg and 400 mgVIDEX EC6/1/2004

Non-Orange Book Patents for Bristol Myers

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,371,761Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
7,005,435Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
6,979,694 Cyclic protein tyrosine kinase inhibitors► Subscribe
7,691,846Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
6,989,391Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
9,382,219Cyclic protein tyrosine kinase inhibitors► Subscribe
6,110,946 Antivirally active heterocyclic azahexane derivatives► Subscribe
8,242,270Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors► Subscribe
8,188,120Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
7,091,223Cyclic protein tyrosine kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bristol Myers Drugs

Country Document Number Estimated Expiration
Russian Federation2345993► Subscribe
Hong Kong1052508► Subscribe
Australia2004223828► Subscribe
World Intellectual Property Organization (WIPO)03026652► Subscribe
Denmark1067936► Subscribe
Hong Kong1042433► Subscribe
Russian Federation2005107463► Subscribe
TaiwanI351404► Subscribe
Australia753604► Subscribe
Slovenia0974356► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bristol Myers Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90029-5Sweden► SubscribePRODUCT NAME: INSULIN DEGLUDEK
2013000061Germany► SubscribePRODUCT NAME: INSULIN DEGLUDEC IN ALLEN DURCH DAS BASISPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/12/807/001 EU/1/12/807/004-005 EU/1/12/807/007-009 EU/1/12/807/012-013 EU/1/12/807/015 20130121
C0046Belgium► SubscribePRODUCT NAME: DOXORUBICIN HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/96/011/001 19960624
C0018France► SubscribePRODUCT NAME: ESTRADIOL VALERATE; DIENOGEST; NAT. REGISTRATION NO/DATE: NL35170 20081210; FIRST REGISTRATION: BE327792 20081103
C0004Belgium► SubscribePRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306
C0006Belgium► SubscribePRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505
00032Netherlands► SubscribePRODUCT NAME: EFAVIRENZ; REGISTRATION NO/DATE: EU/1/99/110/001-004, EU/1/99/111/001-004 19990528
C0006France► SubscribePRODUCT NAME: PIOGLITAZONE/METFORMINE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/06/354/001 DU 20060728; REGISTRATION NO/DATE AT EEC: EU/1/06/354/001 DU 20060728
496Luxembourg► SubscribePRODUCT NAME: COMBINAISON DE DAPAGLIFLOZINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DE METFORMINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,TELLE QUE PROTEGEE PAR LE BREVET DE BASE EP1506211 B1
C/GB96/036United Kingdom► SubscribePRODUCT NAME: INSULIN LISPRO, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY-ACCEPTABLE SALT; REGISTERED: CH 53290 19951123; CH 53553 19951123; UK EU/1/96/007/001 19960430; UK EU/1/96/007/002 19960430; UK EU/1/96/007/003 19960430
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
US Army
US Department of Justice
Boehringer Ingelheim
Medtronic
UBS
Colorcon
Citi
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot